Home  |  Contact

Cellosaurus WM266-4 (CVCL_2765)

[Text version]

Cell line name WM266-4
Synonyms WM-266-4; WM 266-4; WM-2664; WM2664; WM 2664; WM266; WM-266-mel; WM266mel; WC00097
Accession CVCL_2765
Resource Identification Initiative To cite this cell line use: WM266-4 (RRID:CVCL_2765)
Comments Part of: BRAF genetic alteration cell panel (ATCC TCP-1032).
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: MD Anderson Cell Lines Project.
Part of: Wistar Institute melanoma cell line collection.
Doubling time: ~30 hours (PBCF).
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Heterozygous for BRAF p.Val600Asp (c.1799_1800delTGinsAT) (ATCC; Wistar; PubMed=12068308; PubMed=19799798; PubMed=29492214).
Hemizygous for PTEN deletion (Wistar).
HLA typing Source: PubMed=15592718
Class I
HLA-AA*02:01,29:02
HLA-BB*13:02,44:03:01
HLA-CC*06:02,16:01
Class II
HLA-DPDPB1*02:01:02,02:01:02
HLA-DQDQB1*02:01,02:01
HLA-DRDRB1*07:01,07:01

Source: PubMed=25960936
Class I
HLA-AA*02:01,29:01
HLA-BB*13:02,44:02
HLA-CC*06:02,06:02
Class II
HLA-DQDQB1*06:04,06:04
HLA-DRDRB1*07:01,14:103
Disease Melanoma (NCIt: C3224)
Derived from metastatic site: Right thigh skin.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_0040 ! WM115
CVCL_L033 ! WM165-1
CVCL_RN55 ! WM165-2
CVCL_6795 ! WM239A
CVCL_RN56 ! WM239B
CVCL_RN57 ! WM266-1
CVCL_RN58 ! WM266-2
CVCL_RN59 ! WM266-3
Sex of cell Female
Age at sampling 55Y
Category Cancer cell line
STR profile Source(s): ATCC; ESTDAB; KCLB; Wistar

Markers:
AmelogeninX
CSF1PO12
D2S133819
D3S135815,18
D5S81813
D7S8208
D8S117913,15
D13S31712,13
D16S53911,12
D18S5121
D19S43313
D21S1129
FGA21,23
TH017,9
TPOX8,11
vWA15,17

Run an STR similarity search on this cell line
Web pages https://www.wistar.org/our-scientists/meenhard-herlyn
http://www.rockland-inc.com/Product.aspx?id=51768
https://physics.cancer.gov/docs/bioresource/skin/NCI-PBCF-CRL1676_WM-266-4_SOP-508.pdf
http://tcpaportal.org/mclp/
Publications

PubMed=3856042; DOI=10.1093/jnci/74.2.283
Herlyn M., Balaban G., Bennicelli J.L., Guerry D. IV, Halaban R., Herlyn D., Elder D.E., Maul G.G., Steplewski Z., Nowell P.C., Clark W.H., Koprowski H.
Primary melanoma cells of the vertical growth phase: similarities to metastatic cells.
J. Natl. Cancer Inst. 74:283-289(1985)

PubMed=4053039
Herlyn M., Thurin J., Balaban G., Bennicelli J.L., Herlyn D., Elder D.E., Bondi E., Guerry D. IV, Nowell P.C., Clark W.H., Koprowski H.
Characteristics of cultured human melanocytes isolated from different stages of tumor progression.
Cancer Res. 45:5670-5676(1985)

PubMed=3020539; DOI=10.1073/pnas.83.19.7197
Westermark B., Johnsson A., Paulsson Y., Betsholtz C., Heldin C.-H., Herlyn M., Rodeck U., Koprowski H.
Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor.
Proc. Natl. Acad. Sci. U.S.A. 83:7197-7200(1986)

PubMed=2253310; DOI=10.1007/BF00046337
Herlyn M.
Human melanoma: development and progression.
Cancer Metastasis Rev. 9:101-112(1990)

PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=15467732; DOI=10.1038/sj.onc.1208152
Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J., Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.
Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Oncogene 23:8796-8804(2004)

PubMed=15592718; DOI=10.1007/s00262-004-0561-5
Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A., Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G., Garrido F.
High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
Cancer Immunol. Immunother. 54:141-148(2005)

PubMed=17308088; DOI=10.1158/0008-5472.CAN-06-3311
Shields J.M., Thomas N.E., Cregger M., Berger A.J., Leslie M., Torrice C., Hao H., Penland S., Arbiser J.L., Scott G., Zhou T., Bar-Eli M., Bear J.E., Der C.J., Kaufmann W.K., Rimm D.L., Sharpless N.E.
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.
Cancer Res. 67:1502-1512(2007)

PubMed=19799798; DOI=10.1186/1471-2407-9-352
Casula M., Muggiano A., Cossu A., Budroni M., Caraco C., Ascierto P.A., Pagani E., Stanganelli I., Canzanella S., Sini M.C., Palomba G., Palmieri G.
Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy.
BMC Cancer 9:352-352(2009)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21424129; DOI=10.3892/or.2011.1220
Manca A., Sini M.C., Izzo F., Ascierto P.A., Tatangelo F., Botti G., Gentilcore G., Capone M., Mozzillo N., Rozzo C., Cossu A., Tanda F., Palmieri G.
Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Oncol. Rep. 25:1495-1502(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:E954893-E954893(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29492214; DOI=10.18632/oncotarget.23989
Sini M.C., Doneddu V., Paliogiannis P., Casula M., Colombino M., Manca A., Botti G., Ascierto P.A., Lissia A., Cossu A., Palmieri G.
Genetic alterations in main candidate genes during melanoma progression.
Oncotarget 9:8531-8541(2018)

Cross-references
Cell line collections ATCC; CRL-1676
Coriell; WC00097 - Discontinued
ECACC; 91061233 - Discontinued
KCLB; 21676
Cell line databases/resources CLDB; cl4726
CCLE; WM2664_SKIN
Cell_Model_Passport; SIDM00979
CGH-DB; 9312-4
ESTDAB; ESTDAB-076
LINCS_LDP; LCL-1259
Lonza; 1375
Ontologies BTO; BTO:0001595
CLO; CLO_0009612
CLO; CLO_0009615
EFO; EFO_0006774
Biological sample resources BioSample; SAMN05292442
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM827418
GEO; GSM887737
GEO; GSM888832
GEO; GSM1138792
GEO; GSM1670578
Other Wikidata; Q54994222
Polymorphism and mutation databases Cosmic; 687444
Cosmic; 905225
Cosmic; 932718
Cosmic; 972276
Cosmic; 1022277
Cosmic; 1054856
Cosmic; 1155273
Cosmic; 1238103
Cosmic; 1295343
Cosmic; 1303070
Cosmic; 1458970
Cosmic; 1459638
Cosmic; 1477409
Cosmic; 1507624
Cosmic; 1949557
Cosmic; 2163804
Cosmic; 2233687
Cosmic; 2651885